Role of lymphadenectomy in endometrioid endometrial cancer

Objective: To assess the risk factors associated with node involvement. Study design: In the period 1990-2008 a total of 265 endometrial cancers were treated in the Institut Universitari Dexeus. We analysed the rate of myometrial invasion, tumour grade, histological type and node involvement. Results: Overall, 86% of tumours were endometrioid, 5.3% papillary serous, 4.9% mixed and 2.6% endometrial stroma sarcoma. Among those with endometrioid histology, lymphadenectomy was not performed (NL) in 85 cases (37.2%), whereas pelvic lymphadenectomy (PL) or pelvic and aortic lymphadenectomy (PAL) was carried out in 84 (36.84%) and 59 patients (25.87%), respectively. In NL patients the overall disease-free survival (DFS) rate at five years was 92.8%. In the PL group, node involvement was observed in 2.4% of cases and the five-year DFS rate was 92.3%. Among PAL patients, 18.6% showed node involvement (72.7% positive pelvic nodes and 63.6% aortic). Aortic involvement was present in 5.9% of cases when there was no pelvic disease, whereas in the presence of positive pelvic nodes the rate of aortic involvement was 50%. The DFS rate at five years was 93.6%. Referring to the risk factors, when infiltration was > 50% of the myometrium, lymph node involvement occurred in 37% of cases and G3 tumors in 45.5%. Conclusions: Node involvement is more commonly observed in cases with > 50% myometrial invasion and G3, accounting for 25% of cases that can be considered as at-risk patients. When node involvement is present it is equally distributed between the pelvic and aortic levels. As node involvement is a predictive factor for distant metastasis, the 25% of patients considered to be at risk should undergo pelvic and aortic lymphadenectomy

Endometrial cancer; Lymphadenectomy; Management; Paraaortic lymph node; Pelvic lymph node

[1] Mariani A., Dowdy S.C., Cliby W.A., Haddock M.G., Keeney

G. L., Lesnick T.G. et al.: “Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients”. Gynecol. Oncol., 2006, 101, 200.

[2] Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D. et al.: “Gynecologic Oncology Group. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744. Erratum in: Gynecol. Oncol., 2004, 94, 241.

[3] Creutzberg C.L.: “GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma?”. Gynecol. Oncol., 2004, 92, 740.

[4] Siu S.S., Lo K.W., Cheung T.H., Yim S.F., Chung T.K.: “Is aortic lymphadenectomy necessary in the management of endometrial carcinoma?”. Eur. J. Gynaecol. Oncol., 2007, 28, 98.

[5] Boronow R.C., Morrow C.P., Creasman W.T., DiSaia P.J., Silverberg S.G., Miller A. et al.: “Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study”. Obstet. Gynecol., 1984, 63, 825.

[6] Richard C. Boronow.: “Endometrial cancer and lymph node surgery: the spins continue. A case for reason”. Gynecol. Oncol., 2008, 111, 3.

[7] Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Wárlám-Rodenhuis C.C. et al.: “PORTEC (Post Operative Radiation Therapy in Endometrial Carcinoma) Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial”. Lancet, 2000, 355, 1404.

[8] The writing committee on behalf of the ASTEC study group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet, 2009, 373, 125.

[9] Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J. L., Heintz A.P. et al.: “Carcinoma of the corpus uteri”. J. Epidemiol. Biostat., 2001, 6, 47.

[10] Podratz K.C., Mariani A., Webb M.J.: “Staging and therapeutic value of lymphadenectomy in endometrial cancer”. Gynecol. Oncol., 1998, 70, 163.

[11] Orr Jr J.W., Holimon J.L., Orr P.F.: “Stage I corpus cancer: is teletherapy necessary?”. Am. J. Obstet. Gynecol., 1997, 176, 777.

[12] Mariani A., Webb M.J., Galli L., Podratz K.C.: “Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer”. Gynecol. Oncol., 2000, 76, 348.

[13] Bristow R.E., Zahurak M.L., Alexander C.J., Zellars R.C., Montz F. J.: “FIGO Stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival”. Int. J. Gynecol. Cancer, 2003, 13, 664.

[14] Cragun J.M., Havrilesky L.J., Calingaert B., Synan I., Secord A.A., Soper J.T. et al.: “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer”. J. Clin. Oncol., 2005, 23, 3668.

[15] Abu-Rustum N.R., Iasonos A., Zhou Q., Oke E., Soslow R.A., Alektiar K.M. et al.: “Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma?”. Am. J. Obstet. Gynecol., 2008, 198, 457.

[16] Chan J.K., Cheung M.K., Huh W.K., Osann K., Husain A., Teng N.N. et al.: “Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients”. Cancer, 2006, 107, 1823.

[17] Mariani A., Dowdy S.C., Cliby W.A., Haddock M.G., Keeney

G. L., Lesnick T.G. et al.: “Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients”. Gynecol. Oncol., 2006, 101, 200.

[18] Benedetti Panici P., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G. et al.: “Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial”. J. Natl. Cancer Inst., 2008, 100, 1707.

[19] Höckel M., Dornhöfer N.: “Treatment of early endometrial carcinoma: is less more?”. Lancet, 2009, 373, 97.

[20] Amant F., Neven P., Vergote I.: “Lymphaedectomy in endometrial cancer” - Author’s reply. Lancet, 2009, 373, 1170 .

[21] Hakmi A.: “Lymphadenectomy in endometrial cancer” - Author’s reply. Lancet, 2009, 373, 1170.

[22] Mourits M.J., Bijen C.B., de Bock G.H.: “Lymphadenectomy in endometrial cancer” - Author’s reply. Lancet, 2009, 373, 1170.

[23] Nout R.A., Putter H., Jürgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M. et al.: “Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results ofthe randomized PORTEC-2 trial”. J. Clin. Oncol., 2009, 27, 3547.

[24] Mariani A., Dowdy S.C., Cliby W.A., Gostout B.S., Jones M.B., Wilson T.O., Podratz K.C.: “Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging”. Gynecol. Oncol., 2008, 109, 11.

[25] Nomura H., Aoki D., Suzuki N., Susumu N., Suzuki A., Tamada Y. et al.: “Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer”. Int. J. Gynecol. Cancer, 2006, 16, 799.

[26] Cragun J.M., Havrilesky L.J., Calingaert B., Synan I., Secord A.A., Soper J.T. et al.: “Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer”. J. Clin. Oncol., 2005, 23, 3668.

[27] Orr J.W.: “Surgical management of endometrial cancer: how much is enough?”. Gynecol. Oncol., 2008, 109, 1.

[28] Orr J.W., Naumann W.R., Escobar P.: “Attitude is a little thing that makes a big difference”. Winston Churchill, Gynecol. Oncol., 2008, 109, 147.

[29] Orr J.W.: “Surgical staging of endometrial cancer: does the patient benefit?”. Gynecol. Oncol., 1998, 71, 335.

[30] Case A.S., Rocconi R.P., Straughn Jr. J.M., Conner M., Novak L., Wang W., Huh W.K.: “Prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer”. Obstet. Gynecol., 2006, 108, 1375.

[31] Tresserra F., Martinez M.A., Kanjou N., Cusidó M., Fabregas R., Labastida R.: “Intraoperative assessment of myometrial invasion in endometrioid adenocarcinoma”. Arch. Virchow., 2008, 452 (suppl. 1), 77.

[32] Petru E., Lück H.J., Stuart G., Gaffney D., Millan D., Vergote I.: “Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2009, 143, 69.

[33] Selman T.J., Mann C.H., Zamora J., Khan K.S.: “A systematic review of tests for lymph node status in primary endometrial cancer”. BMC Women’s Health, 2008, 8.